Detail akcie Celldex Theraptc Rg online

Business Summary: Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Celldex Therapeutics Inc revenues decreased 46% to $1.4M. Net loss increased 61% to $110.4M. Revenues reflect Contracts and Grants decrease of 48% to $1.4M. Higher net loss reflects Novel Therapeutics segment loss increase of 46% to $126.6M. Basic Earnings per Share excluding Extraordinary Items decreased from -$1.10 to -$1.66.